Products & Services · Total revenues

Yeztugo — Total revenues

This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2025
Last reportedQ1 2026
Rolls up toTotal Revenue

How to read this metric

An increase indicates strong market penetration, successful patient retention, or favorable pricing adjustments, while a decrease may signal increased competition, patent expirations, or shifts in clinical treatment guidelines.

Detailed definition

This metric represents the total gross revenue generated from the sale of the Yeztugo product line within the company's...

Peer comparison

Comparable to specific drug or therapeutic class revenue lines reported by other major biopharmaceutical companies, often benchmarked against market share in the HIV or infectious disease therapeutic categories.

Metric ID: gild_segment_yeztugo_total_revenues

Historical Data

2 periods
 Q1 '25Q1 '26
Value$0.00$166.00M
Range$0.00$166.00M

Frequently Asked Questions

What is Gilead Sciences's yeztugo — total revenues?
Gilead Sciences (GILD) reported yeztugo — total revenues of $166.00M in Q1 2026.
What does yeztugo — total revenues mean?
The total sales revenue generated by the Yeztugo product line.